Table 1.

Clinical and demographic characteristics of women with systemic lupus erythematosus (SLE) who have normal pregnancies and women with SLE who eventually developed preeclampsia.

VariableNormal Pregnancies, n = 75Late-onset Preeclampsia, n = 22pEarly-onset Preeclampsia, n = 20p
Maternal age, yrs29.8 ± 4.926.1 ± 5.50.02a29.3 ± 5.8
Body mass index, kg/m226.4 ± 4.426.0 ± 3.628.4 ± 5.1
Gravidity2 (1–6)2 (1–6)2 (1–6)
Miscarriage0 (0–4)0 (0–2)0 (0–4)
Nulliparity, n (%)32 (42.7)5 (22.7)5 (25.0)
Prior preeclampsia, n (%)9 (12.0)3 (13.6)5 (25.0)
Smoker, n (%)18 (24.0)3 (13.6)2 (10.0)
SLE disease duration, yrs5.8 ± 2.95.2 ± 3.84.3 ± 2.8
PDN dosage at followup, mg/day5 (0–60)10 (0–50)0.01a5 (0–50)
Treatment with chloroquine, n (%)31 (41.3)5 (22.7)9 (45.0)
Treatment with azathioprine, n (%)10 (13.3)5 (22.7)2 (10.0)
Antiphospholipid syndrome, n (%)8 (10.7)5 (22.7)10 (50.0)< 0.001a
Previous SLE manifestations to pregnancy, n (%)
  Renal involvement27 (36.0)13 (59.1)5 (25.0)
  Arthritis64 (85.3)19 (86.4)20 (100.0)
  Mucocutaneous54 (72.0)15 (68.2)12 (60.0)
  Hematological6 (8.0)6 (27.3)0.04a5 (25.0)
  Neurological2 (2.7)1 (4.5)1 (5.0)
  Serositis3 (4.0)0 (0.0)3 (15.0)
Chronic hypertension4 (5.3)0 (0.0)3 (15.0)
Serum creatinine*, mg/dl0.6 (0.32–0.85)0.6 (0.48–1.17)0.6 (0.42–1.94)
Creatinine clearance*, ml/min/1.73 m2135.4 ± 24.2115.8 ± 33.40.02a133.5 ± 35.8
24-h proteinuria*, mg102.4 (25.8–3129.2)159.2 (54.2–6424.7)0.01a110.8 (48.9–3362.1)
Quiescent renal lupus, n (%)8 (10.7)8 (36.4)0.008a4 (20.0)
SLE flares during pregnancy, n (%)6 (8.0)5 (22.7)2 (10.0)
Gestational age at delivery, weeks38.5 ± 0.636.0 ± 1.7< 0.001a27.2 ± 4.5< 0.001a,b
Infant birth weight, g3019 ± 2432103 ± 350< 0.001a786 ± 405< 0.001a,b
Small for gestational age infant, n (%)016 (72.7)< 0.001a15 (75.0)< 0.001a
Stillbirths or neonatal deaths, n (%)0012 (60.0)< 0.001a,b
Maternal death, n (%)001 (5.0)
  • Plus-minus values are means ± SD; other values are medians (range), except where indicated.

  • * at enrollment. P value is given only for significant differences.

  • a versus normal pregnancies.

  • b versus late-onset preeclampsia after application of appropriate statistical tests. PDN: prednisone.